Loading…
← CockpitCompetitor Analysis › 688073.SS Bide Pharmatech Co. Ltd. Class AOpen in the cockpit ↗

Bide Pharmatech Co. Ltd. Class A688073.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Shanghai-area CDMO/CRO providing custom pharmaceutical intermediate and API research and manufacturing services.

≈ A small Chinese pharma-intermediate CDMOMomentum strong 75
Mkt cap
$801M
US dollars, full cap
Free float
39%
of shares outstanding
$/day
$43.1M
20-day average traded
Fwd P/E
24.3×
forward earnings
ROIC−WACC
+7.3 pp
WACC 11.5%
Hurdle
-14 pp
Req g minus delivered
Next earnings
162 days
29 Apr 2027
Close · CNYCN¥60.91
1D-3.8%
1W-10.7%
1M-3.0%
3M-28.2%
6M+10.2%
YTD-0.2%
1Y-14.7%
ATR %7.7%
52w lowhigh31.5% off high

What Bide Pharmatech does

Shanghai-area CDMO/CRO providing custom pharmaceutical intermediate and API research and manufacturing services.

Sells a very large catalogue of ready-made chemical building blocks that drug researchers order like parts, so revenue follows the steady stream of discovery work and small repeat orders, not large single contracts. Custom synthesis and manufacturing for drug developers are a smaller add-on.

In one line: A small Chinese pharma-intermediate CDMO.

Products and services

  • Custom pharmaceutical intermediates
  • Building-block chemical libraries
  • CDMO manufacturing

Customers

  • Global and Chinese pharma/biotech developers

Where it sits in the supply chain

  • Pharma services
  • Contract research and manufacturing
  • Pharmaceutical intermediates

What could go right

  • Global outsourced drug-development demand

What could go wrong

  • Biotech funding cycle sensitivity
  • Customer concentration

Moat: narrow (process know-how, switching costs). Chemistry know-how and qualified supply relationships built into a drug's regulatory filing are sticky.

Headquarters: Shanghai, China · Employees: 734

Named competitors

Bide Pharmatech at a glance

Size Bide Pharmatech (688073.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $801M, the 2583rd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥60.91 on 18 Nov 2026.

Performance Over six months the shares gained 10.2%, against -8.3% for the median peer and -20.0% for the China market (cap-weighted) — 5th highest of 19 in its peer set.

Growth Revenue grew 9.9% over the last twelve months (peer median +2.1%); the operating margin is 18.8% (peer median 5.0%).

Valuation It trades at 24.3× forward earnings against a peer median of 10.8× (3rd most expensive of 8).

Price implies For today's price to make sense, revenue must grow about 14% a year for seven years (Req g). Recent delivered growth is +28%, so the hurdle is -14 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 7.3 points above its cost of capital (11.5% WACC).

Next results Next results expected around 29 Apr 2027 (exchange calendar; dates can move).

Relative performance

10012515021 May 202621 Aug 202618 Nov 2026688073.SS 112Peer median 92
Six months, rebased to 100: Bide Pharmatech against the median of its 20 peers (local-currency closes).

Bide Pharmatech financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.40BCN¥1.32BCN¥1.10BCN¥1.09BCN¥830M
Revenue growth—+20%+1%+31%—
Gross profitCN¥691MCN¥566MCN¥430MCN¥414MCN¥352M
EBITDAn/aCN¥227MCN¥154MCN¥140MCN¥170M
Net incomeCN¥196MCN¥152MCN¥117MCN¥110MCN¥146M
Free cash flowCN¥191MCN¥12.9MCN¥74.8M-CN¥118M-CN¥8.54M
Capital expenditureCN¥21.6MCN¥24.3MCN¥88.3MCN¥61.1MCN¥38.4M
Total debtCN¥130MCN¥141MCN¥82.4MCN¥57.3MCN¥40.8M

Quarterly statements and history in the cockpit →

Bide Pharmatech competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%+150%-50%-25%0%+25%RIGLSUVENSANOFICOLLORICGUDIRWD6078002349ARDX000411002082603229BLISSGVS300267688073.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Bide Pharmatech is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%+30%0×100×200×RIGLSANOFICOLLGUDIRWD6078ARDX688073.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Bide Pharmatech is the large dot.

Capital: growth delivered against growth the price implies

-40%-20%0%+20%-25%0%25%RIGLSANOFICOLLGUD002349002082BLISSGVS002390688073.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Bide Pharmatech is the large dot.

Bide Pharmatech competitors and peer comparison

Head to head with its named competitors (688073.SS vs 2359.HK vs 300363.SZ vs 002821.SZ)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Bide Pharmatech 688073.SS$801M+10%+10%19%24.3×13.9%
Wuxi Apptec 2359.HK$64.1B+51%+38%44%19.5×8.4%
Porton Pharma Solutions 300363.SZ$1.66B+37%+6%-2%n/a2.1%
Asymchem Laboratories (Tianjin) 002821.SZ$7.27B+20%+18%17%37.4×n/a

How Bide Pharmatech compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Bide Pharmatech against its 20 peers (data as of 18 Nov 2026)
Measure688073.SSPeer medianRank in peer set
1-month return-3.0%-3.7%10th highest of 19
6-month return+10.2%-8.3%5th highest of 19
Distance from 52-week high-31.5%-34.8%9th highest of 19
Revenue growth (TTM)+9.9%+2.1%6th highest of 19
Operating margin18.8%5.0%5th highest of 19
Forward P/E24.3×10.8×3rd most expensive of 8
Growth the price implies (Req g, 7 yrs)13.9%4.6%4th most demanding of 10
Growth delivered (Del g)+27.7%+10.1%highest of 10
Hurdle (Req g minus delivered)-13.8 pp-5.1 pp4th least demanding of 10
ROIC minus cost of capital+7.3 pp-2.3 pp3rd highest of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Bide Pharmatech 688073.SSChina$801M+10%+10%19%24.3×13.9%+27.7%
Rigel Pharmaceuticals RIGLUnited States$801M+48%+2%26%10.8×1.5%+22.1%
Suven Life Sciences SUVEN.NSIndia$803M-1%+55%-4,452%n/an/an/a
Sanofi India SANOFI.NSIndia$797M0%-6%26%19.6×16.3%-8.7%
Collegium Pharmaceutical COLLUnited States$806M-24%+8%15%3.7×-2.6%+20.3%
Oric Pharmaceuticals ORICUnited States$795M-9%n/an/an/an/an/a
Knight Therapeutics GUD.TOCanada$792M+41%+36%6%42.2×6.6%+17.7%
Ironwood Pharmaceuticals IRWDUnited States$791M+22%+18%63%3.5×n/an/a
Bambusa Therapeutics BBTXUnited States$791Mn/an/an/an/an/an/a
Hygeia Healthcare 6078.HKHong Kong$811M-3%+2%14%10.4×4.6%+22.5%
Jinghua Pharmaceutical 002349.SZChina$785M-8%+2%20%n/a-2.5%+2.6%
Ardelyx ARDXUnited States$784M-50%+18%-8%252.9×n/an/a
Zhejiang Int'l 000411.SZChina$783M-21%+3%3%n/an/an/a
Wanbangde Pharmaceutical 002082.SZChina$823M-52%-38%-10%n/a27.7%-39.5%
Sichuan Neautus Traditional Chinese 2206.HKHong Kong$779Mn/a+7%8%n/an/an/a
Zhejiang Ausun Pharmaceutical 603229.SSChina$824M-34%+1%0%n/an/an/a
Dezhan Healthcare 000813.SZChina$825M-33%-10%-121%n/an/an/a
Bliss GVS Pharma BLISSGVS.NSIndia$777M+141%+25%18%n/a33.9%+10.1%
Hunan Er-Kang Pharmaceutical 300267.SZChina$829M-40%-14%-29%n/an/an/a
Guizhou Xinbang Pharmaceutical 002390.SZChina$771M-7%-13%4%n/a-3.8%-0.8%
Lexicon Pharmaceuticals LXRXUnited States$766M-22%-46%-147%n/an/an/a

Questions

Who are Bide Pharmatech's main competitors?
Named competitors: WuXi AppTec (2359.HK), Porton Pharma Solutions (300363.SZ), Asymchem Laboratories (002821.SZ). The cockpit's measured peer set (industry) also includes Rigel Pharmaceuticals (RIGL), Suven Life Sciences (SUVEN.NS), Sanofi India (SANOFI.NS), Collegium Pharmaceutical (COLL), Oric Pharmaceuticals (ORIC), Knight Therapeutics (GUD.TO).
Is Bide Pharmatech expensive compared with its peers?
On forward p/e it trades at 24.3× against a peer median of 10.8×, 3rd most expensive of 8 in its peer set. For today's price to make sense, revenue must grow about 14% a year for seven years (Req g). Recent delivered growth is +28%, so the hurdle is -14 pp: the price already allows for a slowdown.
How has Bide Pharmatech stock performed?
Over six months to 18 Nov 2026 the shares returned +10.2% against -8.3% for the median peer; over one year -14.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.